Amber Afzal, MD, MSCI
Assistant Professor
- Phone: 314-362-7216
- Fax: 314-362-8813
- Email: afzalamber@nospam.wustl.edu
Address:
- Suite 1101 Wohl Hospital (office)
Clinical Interest: Benign hematology; Thrombosis; Myelodysplastic syndrome; Myeloproliferative neoplasms
Research: Dr. Afzal focuses on research in the fields of thrombosis, hemostasis, and myeloid malignancies. She studies outcomes of patients afflicted with these disorders using administrative data. She has a particular interest in translating knowledge obtained from outcomes studies to design clinical trials.
Biosketch
Education
- 2010-2004: MBBS/MD, Army Medical College, Rawalpindi, Pakistan
Post-Graduate Training
- 2020-2018: Master of Science in Clinical Investigation, Washington University, St. Louis, MO
- 2019-2016: Fellowship in Hematology and Oncology, Washington University, St. Louis, MO
- 2016-2013: Residency in Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
Academic Positions
- 2022-present: Assistant Professor, Division of Hematology, Department of Medicine, Washington University, St. Louis, MO
- 2021-2019: Instructor, Division of Hematology, Department of Medicine, Washington University, St. Louis, MO
Board Certification
- 2019: ABIM Board Certified in Hematology
- 2019: ABIM Board Certified in Medical Oncology
- 2016: ABIM Board Certified in Internal Medicine
Professional Societies
- 2015-present: Member, American Society of Hematology
- 2019-2016: Member, American Society of Clinical Oncology
Honors & Awards
- ISTH Large Grant 2025
- 2022: ISTH Early Career Award
- 2021: ASH Clinical Research Training Institute
- 2020: Evan Sadler Memorial Travel Award
- 2019: ASH Abstract Achievement Award
- 2019: Best Graduating Hematology and Oncology Fellow, Washington University
- 2019: Citizenship Award in Class of MSCI, Washington University
- 2018: Best Hematology and Oncology Fellow in Academics, Washington University
- 2013: Intern of the Month, Cleveland Clinic Foundation
- 2009: President of Pakistan’s Gold Medal for the Best Medical Student
- 2009: Medical School Class Valedictorian and Recipient of Rector NUST Gold Medal, MBBS
Selected Publications
- Pragmatic Clinical Trial of Fostamatinib as Second-Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial.
Afzal A, Kribs R, Sawhney S, Narang M, Blevins F, Numerof R, Trapani FD, Ladha S, Goel R.EJHaem. 2026 Jul 11;7(4):e70355. doi: 10.1002/jha2.70355. eCollection 2026 Aug.PMID: 42436681 - Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia.
Afzal A, Fiala MA, Jacoby MA, Walter MJ.Blood Adv. 2023 Aug 8;7(15):3838-3841. doi: 10.1182/bloodadvances.2023009818.PMID: 37042968 - Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?
Afzal A, Schaefer J.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):289-293. doi: 10.1182/hematology.2023000514.PMID: 38066879 - Different risks of hemorrhage in patients with elevated international normalized ratio from chronic liver disease versus warfarin therapy, a population-based retrospective cohort study.
Afzal A, Gage BF, Suhong L, Schoen MW, Korenblat K, Sanfilippo KM. J Thromb Haemost. 2022 Jul;20(7):1610-1617. doi: 10.1111/jth.15743. Epub 2022 May 26.PMID: 35491428